Company Quick10K Filing
Keryx Biopharmaceuticals
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 120 $402
10-Q 2018-11-08 Quarter: 2018-09-30
10-Q 2018-08-09 Quarter: 2018-06-30
10-Q 2018-05-10 Quarter: 2018-03-31
10-K 2018-02-21 Annual: 2017-12-31
10-Q 2017-11-07 Quarter: 2017-09-30
10-Q 2017-07-27 Quarter: 2017-06-30
10-Q 2017-05-04 Quarter: 2017-03-31
10-K 2017-03-01 Annual: 2016-12-31
10-Q 2016-11-09 Quarter: 2016-09-30
10-Q 2016-08-05 Quarter: 2016-06-30
10-Q 2016-04-28 Quarter: 2016-03-31
10-K 2016-02-26 Annual: 2015-12-31
10-Q 2015-10-29 Quarter: 2015-09-30
10-Q 2015-08-06 Quarter: 2015-06-30
10-Q 2015-05-04 Quarter: 2015-03-31
10-K 2015-02-27 Annual: 2014-12-31
10-Q 2014-11-06 Quarter: 2014-09-30
10-Q 2014-08-07 Quarter: 2014-06-30
10-Q 2014-05-08 Quarter: 2014-03-31
10-K 2014-03-13 Annual: 2013-12-31
10-Q 2013-11-04 Quarter: 2013-09-30
10-Q 2013-08-02 Quarter: 2013-06-30
10-Q 2013-05-08 Quarter: 2013-03-31
10-K 2013-03-12 Annual: 2012-12-31
10-Q 2012-11-08 Quarter: 2012-09-30
10-Q 2012-08-08 Quarter: 2012-06-30
10-Q 2012-05-09 Quarter: 2012-03-31
10-K 2012-03-02 Annual: 2011-12-31
10-Q 2011-11-04 Quarter: 2011-09-30
10-Q 2011-08-08 Quarter: 2011-06-30
10-Q 2011-05-10 Quarter: 2011-03-31
10-K 2011-03-09 Annual: 2010-12-31
10-Q 2010-11-05 Quarter: 2010-09-30
10-Q 2010-08-09 Quarter: 2010-06-30
10-Q 2010-05-11 Quarter: 2010-03-31
10-K 2010-03-25 Annual: 2009-12-31
8-K 2018-12-11 M&A, Shareholder Rights, Control, Officers, Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-11-08 Earnings, Exhibits
8-K 2018-10-24 Enter Agreement, Other Events
8-K 2018-10-01 Enter Agreement, Other Events, Exhibits
8-K 2018-08-08 Earnings, Exhibits
8-K 2018-07-18 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-06-29 Shareholder Vote
8-K 2018-06-28 Enter Agreement, Sale of Shares, Amend Bylaw, Other Events, Exhibits
8-K 2018-06-14 Officers, Exhibits
8-K 2018-05-25 Regulation FD, Exhibits
8-K 2018-05-08 Enter Agreement, Leave Agreement, Earnings, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-02-12 Officers
8-K 2018-02-07 Earnings, Exhibits
8-K 2017-12-31

Keryx Biopharmaceuticals Financials

KERX Metrics, Comps, Filings

Annual | Quarterly

Business

We are a commercial stage biopharmaceutical company focused on bringing innovative medicines to people with kidney disease. Our long-term vision is to build a multi-product kidney care company. Our marketed product, Auryxia (ferric citrate) tablets, is an orally available, absorbable, iron-based medicine. Auryxia is approved by the U.S. Food and Drug Administration, or FDA, for two indications. Auryxia was originally approved in September 2014 for the control of serum phosphorus levels in patients with chronic kidney disease, or CKD, on dialysis. Additionally, in November 2017, the FDA approved Auryxia for the treatment of iron deficiency anemia in adults with CKD, not on dialysis. With two FDA-approved indications, we will leverage our U.S. clinical and commercial infrastructure to make Auryxia available to millions of people with CKD and either iron deficiency anemia or elevated levels of serum phosphorus, which is referred to as hyperphosphatemia. Ferric citrate is also approved in Japan under the trade name Riona and marketed by our Japanese partner, Japan Tobacco, Inc., or JT, and its subsidiary, Torii Pharmaceutical Co., Ltd., or Torii, and approved in Europe as Fexeric. We use the brand name Auryxia when we refer to ferric citrate for use in the approved indications in the United States. We refer to the product as ferric citrate when referring to its investigational use. Our vision of building a multi-product kidney care company includes expansion of our product portfolio with other medicines that can help patients with kidney disease.

Our business is focused on creating long-term stockholder value by bringing differentiated medicines to the market for the treatment of people with kidney disease that provide meaningful benefits to patients and their healthcare providers. The three pathways to our strategy are:

Maximize Auryxia's Potential


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Seven Stars Cloud (SSC) 520 97% 18.9 15% 165 47 45 43 25 28 536
Aegean Marine Petroleum Network (ANW) 451 0% 1,601 1,011 0 0 0 0 929
Perry Ellis (PERY) 436 38% 5.6 9% 555 170 881 332 50 74 415
Invesco DB Agriculture Fund (DBA) 381 -13.2 -7% 384 0 0 0 -29 -29 381
GraniteShares Gold Trust (BAR) 593 6.0 16% 612 0 0 0 99 99 593
Stellar Acquisition III (STLR) 30 -36.9 -4% 20 3 0 0 -1 -1 30
Farmers Capital Bank (FFKT) 403 8.9 0% 10,900 1,434 0 0 16 35 310
Keryx Biopharmaceuticals (KERX) 402 0% -4.1 -60% 152 206 94 0 -91 -91 376
TCR2 Therapeutics (TCRR) 399 -10.2 -19% 180 8 0 0 -35 -34 350
ETFS Precious Metals Basket Trust (GLTR) 447 7.9 13% 443 0 0 0 57 57 447
Alfacourse (ALFA) 408 -40,331.9 -303% 0 0 0 0 -0 -0 408
Charter Financial (CHFN) 381 7.4 1% 1,626 1,401 0 0 17 36 265
Hennessy Capital Acquisition III (HCAC) 381 0% -35.1 -18% 422 475 432 0 -75 -21 747
Semler Scientific (SMLR) 365 88% 43.9 65% 19 5 24 21 12 8 357
Gulfmark Offshore (GLF) 354 0% 26.1 -6% 417 135 79 0 -27 16 417
PHH (PHH) 354 0% -0.2 -10% 1,442 953 315 0 -138 -149 37
Government Properties Income Trust (GOV) 349 0% 1.1 -1% 4,360 2,694 343 0 -35 298 316
Nuzee (NUZE) 118 16% -10.0 -232% 5 1 2 0 -12 -12 117
JEM Capital (JEM) 403 -20,640.1 -109% 0 0 0 0 -0 -0 403
Fellazo (FLLZ) 345 -1,969.0 -849% 0 1 0 0 -0 -0 345

Balance Sheet ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Cash3515565611294
Accounts Receivable1458
Inventory8421329
PP&E0012545
Assets431961104259141159
Accounts Payable26
Long-Term Debt
Liabilities1281530172150173
Stockholders' Equity3110457387-8-14
Income Statement ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Revenue507102756
Cost of Revenue
Gross Profit
R&D26193252373038
SG&A7719708185100
Tax000100-0
Net Income-28-23-47-112-123-161-163
Cash Flow ($MM)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Cash Operating-23-25-34-81-127-87-93
Cash Investing-44-0-139-2-1
Cash Financing34076113245076